202 related articles for article (PubMed ID: 37760685)
1. Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections.
Berrino PM; Gatti M; Rinaldi M; Brunocilla E; Viale P; Pea F
Antibiotics (Basel); 2023 Aug; 12(9):. PubMed ID: 37760685
[TBL] [Abstract][Full Text] [Related]
2. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
[TBL] [Abstract][Full Text] [Related]
3. Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136770
[TBL] [Abstract][Full Text] [Related]
4. Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing
Gatti M; Bonazzetti C; Pascale R; Giannella M; Viale P; Pea F
Microorganisms; 2024 Jan; 12(1):. PubMed ID: 38257978
[TBL] [Abstract][Full Text] [Related]
5. Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration.
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887225
[TBL] [Abstract][Full Text] [Related]
6. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2024 Mar; 13(4):. PubMed ID: 38666972
[TBL] [Abstract][Full Text] [Related]
7. Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections.
Gatti M; Campoli C; Latrofa ME; Ramirez S; Sasso T; Mancini R; Caramelli F; Viale P; Pea F
Pediatr Infect Dis J; 2023 Nov; 42(11):975-982. PubMed ID: 37523585
[TBL] [Abstract][Full Text] [Related]
8. Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem.
Sanz Codina M; Gatti M; Troisi C; Fornaro G; Pasquini Z; Trapani F; Zanoni A; Caramelli F; Viale P; Pea F
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015211
[TBL] [Abstract][Full Text] [Related]
9. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
10. A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis.
Gatti M; Tedeschi S; Trapani F; Ramirez S; Mancini R; Giannella M; Viale P; Pea F
Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36009906
[TBL] [Abstract][Full Text] [Related]
11. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
[TBL] [Abstract][Full Text] [Related]
12. Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?
Gatti M; Rinaldi M; Bonazzetti C; Gaibani P; Giannella M; Viale P; Pea F
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0096923. PubMed ID: 37843260
[TBL] [Abstract][Full Text] [Related]
13. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
[TBL] [Abstract][Full Text] [Related]
14. Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections.
Gatti M; Cojutti PG; Pascale R; Tonetti T; Laici C; Dell'Olio A; Siniscalchi A; Giannella M; Viale P; Pea F
Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827249
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
Heil EL; Nicolau DP; Farkas A; Roberts JA; Thom KA
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967022
[TBL] [Abstract][Full Text] [Related]
16. Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients.
Gatti M; Cojutti PG; Bartoletti M; Tonetti T; Bianchini A; Ramirez S; Pizzilli G; Ambretti S; Giannella M; Mancini R; Siniscalchi A; Viale P; Pea F
Crit Care; 2022 Jun; 26(1):178. PubMed ID: 35701812
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant
Gatti M; Giannella M; Rinaldi M; Gaibani P; Viale P; Pea F
Antibiotics (Basel); 2022 Dec; 11(12):. PubMed ID: 36551398
[TBL] [Abstract][Full Text] [Related]
19. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Wenzler E; Scoble PJ
Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
[TBL] [Abstract][Full Text] [Related]
20. Defining the pharmacokinetic/pharmacodynamic index of piperacillin/tazobactam within a hollow-fibre infection model to determine target attainment in intensive care patients.
Wenker SAM; Alabdulkarim N; Readman JB; Slob EMA; Satta G; Ali S; Gadher N; Shulman R; Standing JF
JAC Antimicrob Resist; 2024 Apr; 6(2):dlae036. PubMed ID: 38476774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
